VPC
Vestal Point Capital Portfolio holdings
AUM
$1.9B
This Quarter Return
+12.07%
1 Year Return
-12.28%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$1.21B
AUM Growth
+$1.21B
(+28%)
Cap. Flow
+$234M
Cap. Flow
% of AUM
19.34%
Top 10 Holdings %
Top 10 Hldgs %
61.52%
Holding
77
New
29
Increased
16
Reduced
11
Closed
19
Top Buys
| 1 |
Cytokinetics
CYTK
|
$147M |
| 2 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$50.8M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
$47.1M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
$45.2M |
| 5 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
$38.4M |
Top Sells
| 1 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$58.1M |
| 2 |
Merck
MRK
|
$43.6M |
| 3 |
CBAY
Cymabay Therapeutics
CBAY
|
$38.4M |
| 4 |
Vaxcyte
PCVX
|
$33M |
| 5 |
Pacira BioSciences
PCRX
|
$32.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Novavax
NVAX
$1.22B
| $2.39M | 0.2% |
+500,000
| New | +$2.39M |
|
|
52
Pacira BioSciences
PCRX
$1.22B
| $2.34M | 0.19% |
80,000
-1,120,000
| -93% | -$32.7M |
|
53
Atara Biotherapeutics
ATRA
$87.7M
| $1.94M | 0.16% |
+2,800,000
| New | +$1.94M |
|
|
ACHL
54
DELISTED
Achilles Therapeutics plc American Depositary Shares
ACHL
| $1.88M | 0.16% |
1,500,000
+1,391,917
| +1,288% | +$1.74M |
|
|
CMRX
55
DELISTED
Chimerix, Inc.
CMRX
| $1.48M | 0.12% |
1,400,000
| – | – |
|
|
OKUR
56
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$38.7M
| $490K | 0.04% |
295,375
-104,625
| -26% | -$174K |
|
|
AFMD
57
DELISTED
Affimed
AFMD
| $292K | 0.02% |
55,000
-491,067
| -90% | -$2.6M |
|
58
Lyell Immunopharma
LYEL
$215M
| $290K | 0.02% |
+130,000
| New | +$290K |
|
59
Arcutis Biotherapeutics
ARQT
$1.88B
| – | – |
-2,700,000
| Closed | -$8.72M |
|
|
JBIO
60
Jade Biosciences, Inc. Common Stock
JBIO
$252M
| – | – |
-400,000
| Closed | -$9.05M |
|
61
Biogen
BIIB
$20.8B
| – | – |
-75,000
| Closed | -$19.4M |
|
|
BLUE
62
DELISTED
bluebird bio
BLUE
| – | – |
-2,150,000
| Closed | -$2.97M |
|
63
Crinetics Pharmaceuticals
CRNX
$3.2B
| – | – |
-450,000
| Closed | -$16M |
|
64
Edwards Lifesciences
EW
$47.5B
| – | – |
-225,000
| Closed | -$17.2M |
|
|
IMA
65
ImageneBio, Inc. Common Stock
IMA
$154M
| – | – |
-322,671
| Closed | -$636K |
|
|
66
Merck
MRK
$211B
| – | – |
-400,000
| Closed | -$43.6M |
|
67
Nuvalent
NUVL
$5.68B
| – | – |
-200,000
| Closed | -$14.7M |
|
68
Ovid Therapeutics
OVID
$91.7M
| – | – |
-85,429
| Closed | -$275K |
|
|
69
Vaxcyte
PCVX
$4.1B
| – | – |
-525,000
| Closed | -$33M |
|
70
Pyxis Oncology
PYXS
$90.5M
| – | – |
-440,000
| Closed | -$792K |
|
71
Regeneron Pharmaceuticals
REGN
$60.2B
| – | – |
-10,000
| Closed | -$8.78M |
|
72
Revolution Medicines
RVMD
$7.4B
| – | – |
-725,000
| Closed | -$20.8M |
|
73
Sanofi
SNY
$122B
| – | – |
-300,000
| Closed | -$14.9M |
|
74
Teva Pharmaceuticals
TEVA
$21.5B
| – | – |
-200,000
| Closed | -$2.09M |
|
75
Viridian Therapeutics
VRDN
$1.57B
| – | – |
-1,000,000
| Closed | -$21.8M |
|